Supplemental Table 1 Patients with a ≥20% reduction from baseline in worse eye intraocular pressure (IOP) at week 12, intent-to-treat population

Hour, n (%)	Bimatoprost PF (N=302)	Bimatoprost (N=295)	Bimatoprost PF – bimatoprost difference;* p value† (95% CI)‡
8:00 AM	243 (80.5)	242 (82.0)	–1.6; 0.623 (–7.8, 4.7)
10:00 AM	244 (80.8)	231 (78.3)	2.5; 0.451 (–4.0, 9.0)
4:00 PM	212 (70.2)	205 (69.5)	0.7; 0.851 (–6.7, 8.1)

*The treatment difference was calculated based on the percentage of patients with ≥20% reduction in IOP from baseline at each hour of week 12.

†A Pearson's chi-square test or Fisher's exact test was performed to evaluate the equality of proportions between treatment groups.

‡The 95% CI of treatment difference was constructed using the normal approximation for the binomial distribution.

CI, confidence interval; PF, preservative-free.

Supplemental Table 2 Mean diurnal worse eye intraocular pressure (IOP), mmHg, per-protocol population

Visit, Mean±SD	**Bimatoprost PF (N=295)**	**Bimatoprost (N=291)**	**Bimatoprost PF – bimatoprost difference (95% CI)***
Baseline	23.83±2.43	23.80±2.33	0.04 (–0.31, 0.40)
N	295	291	
Week 2	17.13±2.53	16.84±2.44	0.28 (–0.06, 0.62)
N	286	281	
Week 6	16.97±2.69	16.81±2.61	0.13 (–0.23, 0.50)
N	280	278	
Week 12	16.99±2.59	16.82±2.61	0.14 (–0.21, 0.50)
N	281	275	

*CIs are based on the analysis of variance (ANOVA) model with treatment and investigator as the main effects (for baseline) or an analysis of covariance (ANCOVA) model with treatment and investigator as main effects and baseline worse eye mean diurnal IOP as a covariate (for weeks 2, 6 and 12). Estimated difference (bimatoprost PF minus bimatoprost) was based on the least-squares means from the ANOVA or ANCOVA model.

CI, confidence interval; PF, preservative-free; SD, standard deviation.

Supplemental Table 3 All serious adverse events

Adverse event (preferred term), n (%)	**Bimatoprost PF (N=301)**	**Bimatoprost (N=295)**
Overall	2 (0.7)	4 (1.4)
Ovarian cancer*	1 (0.6)	0 (0.0)
Spinal compression fracture	1 (0.3)	0 (0.0)
Atrial fibrillation	0 (0.0)	1 (0.3)
Convulsion	0 (0.0)	1 (0.3)
Death	0 (0.0)	1 (0.3)
Syncope	0 (0.0)	1 (0.3)
Transitional cell carcinoma	0 (0.0)	1 (0.3)

*Percentage based on female population.

PF, preservative-free.